Navigation Links
Roche Extends Tender Offer for Ventana
Date:8/21/2007

TS', 'INTENDS', 'SHOULD', 'SEEKS', 'ESTIMATES', 'FUTURE' OR SIMILAR EXPRESSIONS OR BY DISCUSSION OF, AMONG OTHER THINGS, STRATEGY, GOALS, PLANS OR INTENTIONS. VARIOUS FACTORS MAY CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY IN THE FUTURE FROM THOSE REFLECTED IN FORWARD-LOOKING STATEMENTS CONTAINED IN THIS DOCUMENT, AMONG OTHERS: (1) PRICING AND PRODUCT INITIATIVES OF COMPETITORS; (2) LEGISLATIVE AND REGULATORY DEVELOPMENTS AND ECONOMIC CONDITIONS; (3) DELAY OR INABILITY IN OBTAINING REGULATORY APPROVALS OR BRINGING PRODUCTS TO MARKET; (4) FLUCTUATIONS IN CURRENCY EXCHANGE RATES AND GENERAL FINANCIAL MARKET CONDITIONS; (5) UNCERTAINTIES IN THE DISCOVERY, DEVELOPMENT OR MARKETING OF NEW PRODUCTS OR NEW USES OF EXISTING PRODUCTS, INCLUDING WITHOUT LIMITATION NEGATIVE RESULTS OF CLINICAL TRIALS OR RESEARCH PROJECTS, UNEXPECTED SIDE-EFFECTS OF PIPELINE OR MARKETED PRODUCTS; (6) INCREASED GOVERNMENT PRICING PRESSURES; (7) INTERRUPTIONS IN PRODUCTION; (8) LOSS OF OR INABILITY TO OBTAIN ADEQUATE PROTECTION FOR INTELLECTUAL PROPERTY RIGHTS; (9) LITIGATION; (10) LOSS OF KEY EXECUTIVES OR OTHER EMPLOYEES; AND (11) ADVERSE PUBLICITY AND NEWS COVERAGE. THE STATEMENT REGARDING EARNINGS PER SHARE GROWTH IS NOT A PROFIT FORECAST AND SHOULD NOT BE INTERPRETED TO MEAN THAT ROCHE'S EARNINGS OR EARNINGS PER SHARE FOR ANY CURRENT OR FUTURE PERIOD WILL NECESSARILY MATCH OR EXCEED THE HISTORICAL PUBLISHED EARNINGS OR EARNINGS PER SHARE OF ROCHE.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL VENTANA'S COMMON STOCK. THE TENDER OFFER IS BEING MADE PURSUANT TO A TENDER OFFER STATEMENT ON SCHEDULE TO (INCLUDING THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND OTHER RELATED TENDER OFFER MATERIALS) FILED BY ROCHE WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC) ON JUNE 27, 2007. THESE MATERIALS, AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTAN
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Advantages of Roche Applied Science amplification products
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
5. Prodesse enters patent agreement with Roche
6. NimbleGen extends research market reach
7. TomoTherapy extends reach to Germany
8. Third Wave says patent extends IP reach
9. `Single-sales factor extends tax treatment to tech, service firms
10. Alumni Association extends database help to university
11. Small-Tree extends G5 networking platform to G4, Windows and Linux
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... for an interview with a researcher, please contact the Communications ... each tip. For more information on ORNL and its research ... Contacts. If you have a general media-related question or comment, ... MATERIALS Moving toward nanorobots . . . ...
... Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced ... (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety ... of Adenovirus Disease Following H em ... T ransplantation [HSCT]).The company also announced that the ...
... Mass., July 12, 2011 Comprendia, leading developer ... the life sciences, sponsored by molecular biology reagents ... an online resource that will support epigenetics research. ... implications for oncology, neurology, metabolism and disease mechanisms. ...
Cached Biology Technology:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 3Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 4Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 2Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 3Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 4Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients 5Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application 2Comprendia and New England Biolabs Connect Epigenetics Scientists with New Social Media Application 3
(Date:7/10/2014)... -- Fingerprint Cards, (FPC,s) new mobile touch sensor ... Chinese Top 5 smartphone OEM has selected FPC1021 for a ... October 2014.   FPC is proud to announce ... has a planned date for the start of mass production ... phone of 3 million units. The Chinese OEM wants to ...
(Date:7/10/2014)... Sweden , July 8, 2014 ... has won a new design win (DW). An Asian OEM ... date for mass production start in August 2014.   ... Asian smartphone OEM, which has a planned date for start ... an initial ramp order of SEK 5M, for delivery in ...
(Date:7/10/2014)... Ill. , July 9, 2014 ... (EHR), spurred in large part by meaningful use ... health care providers interact with laboratory information. Now, ... in the field of clinical informatics in order ... To address the educational needs of ...
Breaking Biology News(10 mins):FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... led by Northwestern Medicine scientists has identified how a defective ... disease known as Giant Axonal Neuropathy, or GAN. The finding ... Investigation . GAN is an extremely rare and ... systems of young children. Those affected show no symptoms at ...
... Health today announced that Vetsulin (porcine insulin zinc suspension), the ... is now available to veterinarians throughout the United States. ... from one in 1001 to one in 500, 2 and ... during the past 30 years.3 Today, along with proper diet ...
... cat, it instinctively avoids the feline or risks becoming dinner. ... the sense of smell, provides evidence that a single gene ... by neurobiologist Thomas Bozza has shown that removing one olfactory ... behavior. The gene, called TAAR4, encodes a receptor that responds ...
Cached Biology News:Rare, lethal childhood disease tracked to protein 2Merck Animal Health announces Vetsulin 2Cat and mouse: A single gene matters 2Cat and mouse: A single gene matters 3
...
... The 500 optimization kit is for fine-tuning ... interest. The kit is recommended when you ... system. The kit includes 0.25 g each ... micrometer diameter gold microcarriers, 100 each of ...
... specifically designed for two-dimensional electrophoresis (2D) ... proteins in this marker have been ... across a 2D gel. The pI ... Mol wt: 17,000-89,000 Physical ...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 21 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
Biology Products: